This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Infantile Hemangioma

This study has been completed.
University of Sao Paulo General Hospital
Information provided by (Responsible Party):
Dov Charles Goldenberg, University of Sao Paulo Identifier:
First received: February 18, 2010
Last updated: December 1, 2014
Last verified: December 2014

Infantile Hemangioma (IH) is infancy's most common vascular tumor of infancy and most frequent benign neoplasm.

Treatment of IHs is indicated for approximately 10 to 20% of the cases. Two groups can be defined amongst indications for treatment: patients with absolute indication for treatment and patients with relative indication for treatment.

Absolute or emergency indications comprise function or life threatening situations such as obstruction of airways, obstruction of vision, congestive heart failure, hepatic and coagulation problems.

The following are considered relative indications: cases of large and disfiguring facial hemangiomas; locations that can result in a deformity and/ or permanent scar (nose, ear, lip, glabellar area); extensive face hemangiomas, mainly when there is dermal damage (more probable to scar); local complications such as ulceration, infection and bleeding as well as small hemangiomas in exposed areas (hands and face), mainly if pedunculated due to its ease of excision2,7.

Treatment modalities vary according to the extension, location, presence of complications and the evolutional phase. A combination of various treatments is possible.

Beta blockers are being used in children for approximately 40 years, with proven clinical safety and no cases of death or cardiovascular disease resulting from its direct use. Recently it was reported the use of beta blockers (propanolol) for IH treatment, with significant reduction of tumor volume after introduction of the beta blocker, in a short period of time, with stable results after the end of treatment, which suggested evidences of the benefits of this drug in the tumor treatment The proposal of this study is to assess the use of propanolol in IH treatment, quantifying its effectiveness and safety under continuous monitoring and comparing it to the use of oral corticosteroid. The investigators propose the assessment of the betablockers' use in comparison to the use of corticosteroids in infants with IH in the proliferative or involuting phases, with indication for clinical treatment, and that are not alarming nor urgent; in other words, the current relative indications for treatment.

Condition Intervention Phase
Hemangioma Drug: Propranolol Drug: Prednisone Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Comparative Study of the Use of Beta Blocker and Oral Corticosteroid in the Treatment of Proliferative and Involuting Cutaneous Infantile Hemangioma

Resource links provided by NLM:

Further study details as provided by Dov Charles Goldenberg, University of Sao Paulo:

Primary Outcome Measures:
  • Reduction on tumor volume, based on direct measurement (in centimeters, 2 axis) and photographic analysis (same photo camera, obtained by the same technician) [ Time Frame: weekly in the first two months and twice a week in the following months ]

Secondary Outcome Measures:
  • evidence of collateral effects [ Time Frame: weekly on the first 2 weeks and twice a week on the following months ]

Enrollment: 50
Study Start Date: January 2010
Study Completion Date: December 2014
Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Propranolol
Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses.
Drug: Propranolol
Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
Other Name: beta-blockers
Active Comparator: Prednisone
Oral prednisone , at a dose of 2mg/kg/day, divided in 2 doses.
Drug: Prednisone
Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
Other Names:
  • corticosteroid
  • metilprednisolone

  Show Detailed Description


Ages Eligible for Study:   up to 2 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with ages up to 2 years;
  • Clinically diagnosed hemangioma, in proliferative or involutive phase, with relative indication for clinical treatment, as itemized:
  • lesion causing alteration of regional anatomy with no systemic or functional damage and with a diameter greater than 1 centimeter, or
  • lesion causing aesthetic deformity, or
  • lesion causing local repetitive complications such as ulceration, bleeding or local infection, or
  • lesion causing partial damage of orifices, or
  • lesion causing psychological compromise.
  • Absence of cardiopathy (normal physical examination, anamnesis, echocardiography, electrocardiography and thoracic radiography);
  • Informed consent signed by responsible parties

Exclusion Criteria:

  • Hemangioma with absolute indication for treatment, presenting a risk to function or life;
  • Patients with previous treatment for infantile hemangiomas;
  • Cardiac disease;
  • Pulmonary disease (asthma, bronchiolitis,bronchopulmonary dysplasias)
  • Raynaud syndrome;
  • Pheochromocytoma;
  • Altered echocardiography, even if asymptomatic
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01072045

Instituto de Tratamento do Câncer Infantil (Pediatric Cancer Treatment Institute) - ITACI - ICr-HCFMUSP (Instituto da Criança do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo)
Sao Paulo, Brazil, 05403-900
Sponsors and Collaborators
University of Sao Paulo
University of Sao Paulo General Hospital
Study Director: Dov C Goldenberg, MD Division of Plastic Surgery - Hospital das Clinicas - University of Sao Paulo School of Medicine
  More Information

Additional Information:

Responsible Party: Dov Charles Goldenberg, Professor of Surgery, Division of Plastic Surgery, Haspital dasd Clinicas, University of Sao Paulo, University of Sao Paulo Identifier: NCT01072045     History of Changes
Other Study ID Numbers: CAPPesq0931/09
Study First Received: February 18, 2010
Last Updated: December 1, 2014

Keywords provided by Dov Charles Goldenberg, University of Sao Paulo:
Proliferative hemangioma

Additional relevant MeSH terms:
Hemangioma, Capillary
Port-Wine Stain
Neoplasms, Vascular Tissue
Neoplasms by Histologic Type
Skin Abnormalities
Congenital Abnormalities
Skin Diseases
Adrenergic beta-Antagonists
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Anti-Arrhythmia Agents
Antihypertensive Agents
Vasodilator Agents processed this record on September 25, 2017